CDP323 is a small molecule that was investigated as multiple sclerosis therapy. It was under development by UCB and could become the first oral M.S. inhibitor. Operation
The anticipated action of CDP323 would prevent white blood cells from leaving the blood vessels and thus penetrating the brain, cfr. Natalizumab (Tysabri). Since Relapsing Remitting MS has certain white blood cells responsible for central nervous system damage, it could then reduce the negative effects of inflammation in this first phase of the course of the disease. Results of animal experiments were promising. Development
The research has been in Phase II since mid 2007. About 300 people with M.S. did in Europe (including Belgium & the Netherlands) and the U.S. participate in the study. They were divided into 3 groups including 1 placebo group, 1 group with 500mg CDP323 and the final group with 1000mg CDP323. Conditions include inter alia that previous therapy with interferon was inoperative or non-viable. Results were expected at the end of 2008, early 2009. Authorization by the medical authorities was expected in favorable circumstances in 2013. Phase II clinical trial stopped
UCB and Biogen IDEC announced on 30/06/2009 that the Phase II clinical study of CDP323 for the treatment of recurrent forms of multiple sclerosis (MS) is discontinued.
A first interim efficacy analysis showed that after a 6 month treatment period, patients in this study could not enjoy the expected benefits of CDP323 compared to placebo.
wiki
